# Observational Study of Triple Combination Therapy of Zemidapa Tab. and Metformin in Type 2 Diabetes Mellitus Patients

> **NCT06495281** · — · COMPLETED · sponsor: **LG Chem** · enrollment: 2044 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06495281
- **Lead sponsor:** LG Chem
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-26
- **Primary completion:** 2025-12-03
- **Final completion:** 2025-12-03
- **Target enrollment:** 2044 (ACTUAL)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06495281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06495281, "Observational Study of Triple Combination Therapy of Zemidapa Tab. and Metformin in Type 2 Diabetes Mellitus Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06495281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*